Precipio, Inc. PRPO

Precipio, Inc. (PRPO) and Fulgent Genetics (FLGT) are profiled as contrasting bets in diagnostic testing. PRPO pursues a dual model of clinical labs and proprietary diagnostics, anchored by hematologic pathology services, aiming to turn product opportunities into scalable revenue via expanded distribution and stronger cash generation, reducing reliance on external financing. FLGT expands its pathology footprint with Bako Diagnostics and StrataDx, and invests in AI and digital pathology to boost efficiency, alongside a therapeutic development pipeline leveraging its CleanChemo platform. Valuation shows PRPO at an EV/S of 1.66x vs. FLGT at 1.04x, with both below the broader sector average. The piece concludes FLGT offers more upside due to diversification, acquisitions, AI enablement and therapy options, while PRPO's progress is encouraging but largely reflected in its price. Moderate potential impact as PRPO's cash-generating improvements are positive but unlikely to drastically shift long-term trajectory versus FLGT's broader platform.

Precipio, Inc. (PRPO) shares increased after its Q2 earnings release, supported by strong revenue growth momentum. Q2 earnings beat and revenue strength produced immediate stock gains with moderate effects on near-term sentiment and operations.

Precipio Inc reported record revenue and positive EBITDA in its Q2 2026 earnings call. Record revenue and positive EBITDA indicate improved financial performance that may significantly enhance Precipio's market position and investor outlook.

Precipio, Inc. (PRPO) reported a second quarter 2025 earnings per share (EPS) of $0.049, a significant improvement compared to a loss of $0.83 in the same quarter of 2024. This positive shift indicates a turnaround in the company's financial performance over the year. The substantial improvement in EPS suggests a significant positive shift in financial performance that could influence investor sentiment and the company's future trajectory.

Precipio, Inc. released Q2 2026 earnings call details covering financial results, operational updates and forward guidance. Quarterly earnings disclosure supplies performance data that can shift near-term investor views without guaranteeing structural change.

Precipio, Inc. (PRPO) released its Q2-2026 financial results. Quarterly financial results can move share price but rarely shift long-term company trajectory without major surprises.

Precipio (PRPO) released its Q1 2026 earnings call transcript covering financial results and business updates. Earnings call transcript delivers core quarterly results and outlook that typically drive immediate trading and valuation shifts.

Precipio (PRPO) Q4 2025 earnings transcript released, detailing quarterly financial results, performance metrics and management discussion. Q4 earnings data and outlook typically drive material shifts in valuation and trading activity.

Precipio, Inc. (PRPO) released its Q1 2026 earnings call summary covering financial results and outlook. Quarterly earnings call delivers financial metrics that may shift near-term investor views but rarely redefine long-term company trajectory.

Precipio, Inc. (NASDAQ: PRPO) reported Q1-2025 revenues of $4.9M, a 43% increase year-over-year, despite a 9.5% decline from Q4-2024 due to seasonal factors. Adjusted EBITDA improved significantly to ($108K) from ($1,409K) YoY. Cash used in operations decreased by 93% to ($44K). The Products Division onboarded a new customer and launched two panels, while the Pathology Services Division saw a 54% revenue growth. Management anticipates a return to positive cash flow by Q2 or Q3 and expects continued revenue growth driven by product pipeline momentum and expanded reimbursement opportunities. A recent FDA ruling reversal is expected to enhance engagement with laboratories. A shareholder conference call is scheduled for May 15, 2025. Significant revenue growth and improved margins, along with regulatory changes, are likely to impact future performance positively.

Precipio, Inc. (PRPO) announced financial results for Q1 2026. Quarterly financial results disclosure moderately influences financial performance and investor sentiment.

Precipio, Inc. summarized its Q4 2025 earnings call, highlighting financial results, operational progress, and future guidance. Q4 earnings summary reveals financial performance and strategic updates that moderately influence investor sentiment and stock trajectory.

Precipio announces publication of a joint study with Memorial Sloan-Kettering Cancer Center highlighting its cutting-edge Bloodhound BCR::ABL1 assay for improved leukemia monitoring. Joint study publication with Memorial Sloan-Kettering validates Precipio's innovative BCR::ABL1 assay, boosting credibility, potential partnerships, and investor sentiment.

Precipio, Inc. (PRPO) reported unaudited 2025 revenues of $24.0 million, a 30% increase year-over-year. 30% year-over-year revenue growth to $24M represents a major positive shift in financial performance likely to boost investor sentiment and alter market trajectory.

Precipio, Inc. has made significant progress towards achieving a clean balance sheet by addressing outstanding debts and improving its financial position. The company has implemented strategic measures to enhance liquidity and reduce liabilities, which are expected to positively impact its overall financial health. These steps are part of a broader effort to strengthen the company's operational framework and prepare for future growth opportunities. The company's strategic moves to improve its balance sheet are likely to significantly impact its future performance and investor sentiment.

Precipio, Inc. will present its BCR::ABL1 panel at the 2025 ASH Meeting, highlighting its advancements in hematology diagnostics. This panel is designed to improve the detection and monitoring of BCR::ABL1 fusion genes, which are critical in managing certain types of leukemia. The presentation aims to showcase the company's commitment to innovation in cancer diagnostics and its potential impact on patient care. The showcase of the BCR::ABL1 panel at a prominent medical meeting indicates a significant strategic move that could enhance Precipio's market position and investor sentiment.

Precipio, Inc. (PRPO) experienced a rise in stock price following its solid Q3 earnings report, which highlighted improved cash flow. The company reported significant revenue growth and a reduction in operating losses, indicating a positive trend in financial performance. Investors reacted favorably to the results, reflecting increased confidence in the company's future prospects. The solid Q3 earnings and improved cash flow are likely to significantly impact investor sentiment and the company's future performance.

Precipio, Inc. (PRPO) reported record revenue growth in Q3 2025, highlighting strategic initiatives that contributed to its financial success. The company emphasized its commitment to innovation and expanding its market presence, which has positively impacted investor sentiment and operational performance. Key metrics showcased significant improvements, positioning Precipio favorably within its industry. Record revenue growth and strategic initiatives indicate a significant positive shift in the company's trajectory and market positioning.

Precipio, Inc. (PRPO) reported its financial results for Q3-2025, highlighting key metrics such as revenue growth and operational developments. The company continues to focus on its strategic initiatives aimed at enhancing its market position and expanding its product offerings. Management expressed optimism about future prospects and ongoing projects that could drive further growth. The financial results indicate moderate growth and strategic focus, which may influence investor sentiment and operational performance.

Precipio, Inc. (PRPO) has announced a shareholder update call for Q3-2025, providing an opportunity for investors to gain insights into the company's performance and future strategies. The call is expected to address key developments and financial results, enhancing transparency and engagement with shareholders. The shareholder update call may influence investor sentiment and provide insights into the company's performance, but its overall impact is expected to be limited.

Precipio, Inc. has terminated its at-the-market (ATM) equity offering program, which allowed the company to sell shares to raise capital. The decision comes as part of a strategic shift, with the company focusing on other financing options and operational priorities. This move is expected to impact the company's liquidity and funding strategies moving forward. Terminating the ATM program may affect the company's financial flexibility and funding options.

Precipio, Inc. (PRPO) reported its financial results for Q2-2025, highlighting key metrics such as revenue growth and operational developments. The company emphasized advancements in its product offerings and strategic initiatives aimed at enhancing market presence. Management expressed optimism about future performance and ongoing projects that could drive further growth. Revenue growth and operational developments indicate a moderately noticeable influence on financial performance and market positioning.

Precipio, Inc. (PRPO) has announced a shareholder update call for Q2-2025, providing an opportunity for investors to gain insights into the company's performance and future strategies. The call is expected to cover key developments and financial results, aiming to enhance transparency and engagement with shareholders. The shareholder update call may influence investor sentiment and provide insights into the company's performance, but its overall impact is expected to be limited.

Precipio, Inc. has amended its agreement with its largest warrant holder, allowing for the exercise of 100,000 warrants with cash and 200,000 warrants in a cashless manner. This change reduces the number of shares added to outstanding shares from approximately 300,000 to between 130,000-150,000 and results in a cash inflow of about $1.2 million, down from $3.8 million under normal exercise conditions. Management will discuss this transaction in the upcoming quarterly shareholder call on August 15, 2025. The amendment to the warrant exercise structure is expected to moderately influence financial performance and share dilution.

Precipio, Inc. (PRPO) has been highlighted as a strong buy alongside Arena Group Holdings (AREN) in Barchart’s Top 100 Stocks to Buy, with Precipio ranking 31st. While Arena Group has shown promising digital revenue growth, it faces challenges due to its media business and significant debt. In contrast, Precipio operates in a growing healthcare sector focused on reducing cancer misdiagnoses and has seen a 200% stock increase since a reverse split. Despite its operating losses, Precipio's service revenue is rising, and it anticipates a return to positive cash flow by mid-2025, making it a speculative but potentially rewarding investment for aggressive investors. Precipio's anticipated revenue growth and potential return to profitability could significantly alter its market position.

Precipio Inc (NASDAQ:PRPO) reported a 43% year-over-year revenue increase in Q1 2025, reaching $4.9 million, with adjusted EBITDA improving by 92%. The pathology division saw a 46% increase in test volume and a 53% revenue growth, alongside a rise in gross margins from 24% to 42%. However, revenues decreased by 9.5% from Q4 2024 due to seasonal patterns, and delays in customer adoption were caused by an FDA ruling on laboratory-developed tests. The company is pursuing $1 million from the CARES Act employee retention credit. MolDx approval for next-generation sequencing testing is expected to boost revenue by $0.25 million per quarter. Significant revenue growth and regulatory approvals are likely to enhance future performance.

Precipio, Inc. (PRPO) has announced a shareholder update call for Q1-2025, providing an opportunity for investors to receive insights into the company's performance and strategic direction. The call is expected to cover key developments and future plans, aiming to enhance transparency and engagement with shareholders. The shareholder update call may influence investor sentiment and provide insights into the company's future direction, but its overall impact is expected to be limited.

Precipio Inc (PRPO) achieved break-even by the end of 2024, reporting a 26% revenue growth in Q4 and a 22% growth for the full year. The pathology division exceeded break-even for the second consecutive quarter, while the product division faced challenges with flat revenues and regulatory delays. Steve Miller's return as Chief Commercial Officer is expected to enhance growth in the product division. The company aims to improve customer onboarding and increase market visibility in 2025. Achieving break-even and significant revenue growth, along with strategic leadership changes, are likely to significantly impact future performance.

Precipio, Inc. (NASDAQ:PRPO) reported a full year 2024 net loss of US$4.29 million, a 27% improvement from FY 2023, with a loss per share of US$2.93 compared to US$4.51 in the previous year. Revenue increased by 22% to US$18.5 million. Despite these improvements, Precipio shares have declined by 7.5% over the past week. The company faces two warning signs, one of which is significant. The financial improvements indicate a moderately noticeable influence on future performance, but challenges remain.

Precipio, Inc. (NASDAQ: PRPO) will host its Q4 and year-end 2024 corporate update call on March 31, 2025, at 5:00 PM ET. The call will cover updates on the company's core businesses. Participants can access the call by phone or pre-register online. Questions can be submitted via email, and a replay will be available on the company's website. Precipio focuses on cancer diagnostics, aiming to reduce misdiagnoses through innovative technologies and proprietary products. Investors are encouraged to review information posted on the company's website and social media for updates. The conference call may provide insights into financial performance and strategic direction, impacting investor sentiment.